The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
Official Title: A Pilot Study of Intravenous Topotecan and Vincristine in Combination With Subconjunctival Carboplatin for Patients With a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease (IND# 104,942)
Study ID: NCT00980551
Brief Summary: The investigators are testing subtenon carboplatin in combination with vincristine and topotecan given by vein in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back (recurrent) or is resistant to other treatment (refractory). The goals of this study are: * To decide if the drug combination is a useful treatment for recurrent or refractory retinoblastoma * To test the safety of the drug combination and to see what kind of effects (good and bad) can be expected from the drug combination * To measure visual changes before and after the study therapy * To use a special MRI scan to measure brain function involved in vision processing, both before and after the study therapy In this study, the investigators are also testing a new experimental way of giving carboplatin "subtenon carboplatin". The carboplatin will be given directly in the eye through a needle placed under the covering of the eye. This is to try to get more carboplatin to the retinoblastoma inside the eye.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Name: James Geller, MD
Affiliation: Children's Hospital Medical Center, Cincinnati
Role: PRINCIPAL_INVESTIGATOR